Sign in
AARD Stock Price, Chart, Stats & News
Aardvark Therapeutics, Inc. Common Stock
Save
89.01M
Market cap
–
Current P/E
–
Forward P/E
AARD chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -49.15% |
ROE | -44.59% |
D/E | 0.00x |
Interest coverage ratio | – |
AARD valuation
P/E | – |
P/S | – |
P/B | 0.73x |
P/CF | -1.43x |
P/FCF | -1.43x |
P/OCF | -1.43x |
PEG | 0.29x |
EV multiple | -2.02x |
About
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule.
Similar securities
Based on sector and market capitalization
Report issue